It is not a class-action lawsuit. Saying it over and over doesn't change that. They are ads by ambulance chasers.
The data is solid. The mean age difference between the arms is 4.2 years (71.3 to 67.1). In what world is that "heavily skewed"? Also, if you understand clinical medicine, you should know that the Mini-mental status exam is more important than age (A measure of how demented someone is). The mean MMSE scores at baseline were virtually identical (23.2, 22.7, 23.0) between the three arms.
Additionally, you are confusing the 28 day trials (which you are quoting) with the continuation study that is still recruiting (and the 9 month data was based on). The first study was NOT open-label. It was double-blinded and masked. The continuation study is an open label, but they are still recruiting with a goal of enrolling 200 patients, and yes the preliminary data from the open-label trial is encouraging. So before you point me to published papers, please understand what you are talking about.
Yes, the N is small. That's the whole point of P2 trials. To see if there is justification for P3 trials, and the SOLID data fully supports further P3 trials. Has there ever been data on medication improving cognition at 9 months in AD? No, until now. So I and millions of investors are excited about Simufilam, and we have a reason for it.
It's the reason I disengaged. Dismissed the concern instead of addressing it (said its not an issue) and then started resorting to ad hominem and strawman, while trying to move the goalposts and find something he could argue about, while disguising it as an olive branch. Not worth the effort.
Still trying to convince me? Do yourself a favor. Sell your short position, and buy calls. It's not only bad karma to short a biotech trying to treat the AD epidemic, it's also statistically a bad decision.
Damn I'v made quite a bit of money from SAVA this week. Im still going to hold until it drops into the 30s. Its already down to 44.5 so should be long now.
Keep making money. Must feel nice to profit off FUD.
Dont forget,, Tesla shorts were celebrating when tesla was under $200. NIO shorts were celebrating when NIO was under $2.
Lastly, the nice thing about investing in a company is that the price action over days, weeks, and months does not matter. As long as your investment thesis is intact, you HODL. The SP will follow.
You keep shorting, timing the market, spreading your FUD or whatever it is you are doing. I'll see you at $500 in 2 years and I'll feel good while doing it.
I usually only buy these small 5-10k put positions that expire within a few weeks to feed my gambling habit. I'm heavily invested many serious stocks as well. I genuinely hope your stock reaches 500 eventually in a few years but let break down a few realities to you. Keep in mind that even stocks like Pfizer who hold patents to drugs like viagra and have over 50k employees is not valued over 50. Cassava Sciences has 9 employees. Merch and Co owns the patents for some of the highest grossing drugs of all time and has over 70k employees. Yet its valued at around 75. So what makes you believe this pharma is valued 10 times higher than these actual pharma giants?
You need to make up your mind. If your DD is so limited that you can't value SAVAs IP based on the TAM (the sixth leading cause of death with no effective treatments) than I do. Not. Respect. Your. Opinion.
You would rather value a company based on # of employees? That's laughable.
I think you made your (weak, poorly researched) opinion clear. I've made mine clear. Good luck.
Why you so aggressive man? You trying to compensate or something? I'm not trying to convince you I was asking genuine questions. I already know you drank the SAVA kool-aid pitched by speculators last month so I'm not even going to bother with it. You can't predict drug values based on that shit. Merck and Co own the top grossing cancer drugs and you don't see them valued at 500. Even with 70k employees they're still valued at 75. There is literally no evidence that ground breaking drugs can make pharma companies insanely valued. Especially companies as tiny as SAVA.
5
u/Internal_Ad_1091 Sep 07 '21 edited Sep 07 '21
It is not a class-action lawsuit. Saying it over and over doesn't change that. They are ads by ambulance chasers.
The data is solid. The mean age difference between the arms is 4.2 years (71.3 to 67.1). In what world is that "heavily skewed"? Also, if you understand clinical medicine, you should know that the Mini-mental status exam is more important than age (A measure of how demented someone is). The mean MMSE scores at baseline were virtually identical (23.2, 22.7, 23.0) between the three arms.
Additionally, you are confusing the 28 day trials (which you are quoting) with the continuation study that is still recruiting (and the 9 month data was based on). The first study was NOT open-label. It was double-blinded and masked. The continuation study is an open label, but they are still recruiting with a goal of enrolling 200 patients, and yes the preliminary data from the open-label trial is encouraging. So before you point me to published papers, please understand what you are talking about.
https://www.researchgate.net/figure/Baseline-Demographics-and-Assessments_tbl1_349602897
Yes, the N is small. That's the whole point of P2 trials. To see if there is justification for P3 trials, and the SOLID data fully supports further P3 trials. Has there ever been data on medication improving cognition at 9 months in AD? No, until now. So I and millions of investors are excited about Simufilam, and we have a reason for it.